Combination therapy for advanced triple negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a new combination of a vitamin A derivative (all-trans retinoic acid), an immunotherapy drug (toripalimab), and chemotherapy for people with advanced triple negative breast cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps shrink or control the cancer better than current treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced triple negative breast cancer that cannot be surgically removed or has spread to other parts of the body.
- Your cancer must be triple negative, meaning it does not have receptors for estrogen, progesterone, or HER2.
- You must have at least one tumor that can be measured on scans (like CT or MRI).
- You must be in good enough health to undergo treatment, with adequate blood counts and kidney/liver function.
- You cannot have had prior treatment with PD-1 or PD-L1 inhibitors (a type of immunotherapy).
- If you are of childbearing age, you must agree to use effective contraception during and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of radiation therapy and immunotherapy for people with advanced triple-negative breast cancer who haven't had chemotherapy for their advanced disease. It aims to see if adding radiation to standard chemotherapy can help shrink tumors and improve outcomes.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with a PARP inhibitor (olaparib) and a chemotherapy drug (paclitaxel) before surgery for early high-risk triple negative breast cancer that is HRD positive. It aims to shrink or eliminate the tumor to improve long-term outcomes.
This trial tests a combination of two drugs (sacituzumab tirumotecan and tagitanlimab) for people with advanced triple-negative breast cancer that has progressed after earlier treatments. The goal is to see if this combination can help control the cancer.
This trial tests a combination of two drugs (camrelizumab and pirfenidone) with chemotherapy to see if it can help people with advanced triple-negative breast cancer. It may offer a new treatment option for those whose cancer has progressed after initial treatment.
This trial tests a combination of an oral vitamin A-based drug (all-trans retinoic acid) and an immunotherapy (toripalimab) for people with advanced triple-negative breast cancer that hasn't responded to at least two prior treatments. The goal is to see if this combination can shrink or control the cancer.
This trial tests if combining an immunotherapy drug (toripalimab) with targeted radiation (SBRT) can help people with triple-negative breast cancer that did not shrink after initial chemotherapy. It aims to improve outcomes before surgery.
Hear when a new Triple Negative Breast Cancer (TNBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.